贝伐珠单抗联合紫杉醇和铂类化疗对晚期转移性宫颈癌的疗效及对T淋巴细胞亚群和肿瘤标志物的影响

Efficacy of Bevacizumab Combined with Paclitaxel and Platinum-Based Chemotherapy in Advanced Metastatic Cervical Cancer and Its Effect on T Lymphocyte Subsets and Tumor Markers

目的探究贝伐珠单抗联合紫杉醇和铂类化疗对晚期转移性宫颈癌的疗效及对T淋巴细胞亚群和肿瘤标志物的影响。方法选取60例在本院接受治疗的晚期转移性宫颈癌患者,随机分为对照组(30例)及治疗组(30例)。所有患者均给予放疗,其中对照组在放疗的基础上给予紫杉醇和铂类化疗,治疗组在对照组的基础上加用贝伐珠单抗治疗。比较2组疼痛情况(视觉模拟评分法(VAS))及生存质量(卡氏生活质量评分(KPS))、临床疗效、T淋巴细胞亚群水平(CD3+、CD4+、CD8+)、肿瘤标志物(糖链抗原125(CA125)、癌胚抗原(CEA)、鳞状上皮癌相关抗原(SCCA))及不良反应发生情况。结果与治疗前比较,两组治疗后VAS评分、血清CA125、CEA、SCCA、CD8+水平均明显降低(P<0.05),且与对照组比较,治疗组降低更明显(P<0.05);两组治疗后KPS评分、CD3+、CD4+水平均明显升高(P<0.05),且与对照组比较,治疗组升高更明显(P<0.05);治疗组总有效率(66.67%)明显高于对照组(40.00%)(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论贝伐珠单抗联合紫杉醇和铂类化疗治疗晚期转移性宫颈癌患者可有效减轻疼痛,提高免疫功能及生活质量,安全有效。

Objective To investigate the efficacy of bevacizumab combined with paclitaxel and platinumbased chemotherapy in advanced metastatic cervical cancer and its effect on T lymphocyte subsets and tumor markers.Methods Sixty patients with advanced metastatic cervical cancer(treated in our hospital)were randomly divided into control(30 cases)and treatment(30 cases)groups.All patients were given radiotherapy;the control group received paclitaxel and platinum-based chemotherapy,whereas the treatment group received the same with added bevacizumab.The pain conditions(visual analog score(VAS))and quality of life(Karl Fischer quality of life(KPS)),clinical efficacy,T lymphocyte subset levels(CD3+,CD4+,and CD8+),tumor markers(carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),and squamous epithelial carcinoma-associated antigen(SCCA))and adverse reactions were compared between the two groups.Results The VAS score,serum CA125,CEA,SCCA,and CD8+level were significantly reduced in both groups after treatment(P<0.05),and it significantly decreased in the treatment group compared with the control group(P<0.05).KPS score,CD3+,and CD4+levels significantly increased after treatment in the two groups(P<0.05),and compared with the control group,the treatment group significantly increased(P<0.05).Moreover,the total effective rate(66.67%)was significantly higher than that in the control group(40.00%)(P<0.05),and no significant difference existed in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Bevacizumab combined with paclitaxel and platinum-based chemotherapy can effectively reduce the pain and improve the immune function and quality of life of patients with advanced metastatic cervical cancer.This chemotherapy is also safe and effective.